hypogonadism%20in%20males%20-%20late-onset
HYPOGONADISM IN MALES - LATE-ONSET
Late onset hypogonadism is defined as clinical and biochemical syndrome characterized by older age, set of typical symptoms, and deficiency in serum testosterone levels.
The quality of life may be decreased and multiple organ systems may be adversely affected.
Prior to the start of testosterone substitution, there should be confirmation of low serum testosterone and a confirmation of need based on clinical findings.
Only if the potential benefit exceeds the risk, then replacement testosterone should be started.

Introduction

  • A type of hypogonadism that has normal pubertal development thus w/ developed normal male secondary sex characteristics
  • Prevalence of hypogonadism increases w/ age
  • Quality of life may be decreased
  • Multiple organ systems may be adversely affected

Definition

  • Late-onset hypogonadism (LOH) is defined as a clinical & biochemical syndrome caused by androgen deficiency characterized by:
    • Older age
    • Set of typical symptoms
    • Deficiency in serum testosterone levels

Signs and Symptoms

  • Decreased sexual desire & erectile quality & frequency; especially nocturnal erections
  • Mood changes, including:
    • Decreases in intellectual activity, cognitive function, spatial orientation ability
    • Fatigue
    • Depression
    • Irritability 
  • Sleep disturbances
  • Decrease in lean body mass w/ decrease in muscle volume & strength
  • Increase in visceral fat
  • Decrease in body hair & skin alterations
  • Osteopenia, osteoporosis & increased risk of bone fractures may develop from a decrease in bone mineral density
  • Hot flushes
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from the large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.
Roshini Claire Anthony, 13 Jun 2019

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

26 Mar 2017
Siblings of men with oligozoospermia are susceptible to any-site cancer and acute lymphoblastic leukaemia, according to a recent study.
07 Aug 2018
While nonseminoma testicular cancer (TC) has a stronger genetic background, seminoma appears to have more familial associations with discordant cancers, a recent study has found.